AG
AXDX

Advisor Group’s Accelerate Diagnostics AXDX Stock Holding History

Advisor Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$136K Sell
805
-17
-2% -$2.81K ﹤0.01% 2699
2019
Q3 		$153K Sell
822
-65
-7% -$12.6K ﹤0.01% 2533
2019
Q2 		$203K Sell
887
-27
-3% -$5.28K ﹤0.01% 2302
2019
Q1 		$193K Sell
914
-70
-7% -$13.1K ﹤0.01% 2311
2018
Q4 		$113K Sell
984
-44
-4% -$6.52K ﹤0.01% 2547
2018
Q3 		$235K Buy
1,028
+48
+5% +$10.6K ﹤0.01% 2037
2018
Q2 		$219K Sell
980
-25
-2% -$5.59K ﹤0.01% 1908
2018
Q1 		$230K Sell
1,005
-40
-4% -$10.5K ﹤0.01% 1865
2017
Q4 		$274K Sell
1,045
-360
-26% -$84.4K ﹤0.01% 1749
2017
Q3 		$315K Buy
1,405
+250
+22% +$61.4K 0.01% 1504
2017
Q2 		$316K Hold
1,155
– – 0.01% 1444
2017
Q1 		$280K Buy
1,155
+345
+43% +$78.8K 0.01% 1424
2016
Q4 		$168K Buy
810
+410
+103% +$97.4K ﹤0.01% 1680
2016
Q3 		$109K Buy
+400
New +$88.5K ﹤0.01% 1941

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Advisor Group's AXDX Position: Q4 2019 in Review

Advisor Group reduced its Accelerate Diagnostics (AXDX) stake by 2.1% in Q4 2019, selling an estimated $2.81K and leaving 805 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

Advisor Group first reported a position in AXDX in Q3 2016 and has held it in 14 quarters since. The position peaked at $316K in Q2 2017. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

  • Advisor Group held 805 shares of Accelerate Diagnostics worth $136K as of Q4 2019.
  • Advisor Group sold 17 Accelerate Diagnostics shares in Q4 2019, an estimated $2.81K.
  • Accelerate Diagnostics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2699 holding.
  • Advisor Group first reported a position in Accelerate Diagnostics in Q3 2016 and has held it in 14 quarters since.
  • Advisor Group's Accelerate Diagnostics position peaked at $316K in Q2 2017.
  • 109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.